1346 related articles for article (PubMed ID: 30514504)
1. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
Marimani M; Ahmad A; Duse A
Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
[TBL] [Abstract][Full Text] [Related]
2. Natural and trained innate immunity against Mycobacterium tuberculosis.
Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
[TBL] [Abstract][Full Text] [Related]
3. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
4. Importance of differential identification of Mycobacterium tuberculosis strains for understanding differences in their prevalence, treatment efficacy, and vaccine development.
Chae H; Shin SJ
J Microbiol; 2018 May; 56(5):300-311. PubMed ID: 29721826
[TBL] [Abstract][Full Text] [Related]
5. Genome wide approaches discover novel Mycobacterium tuberculosis antigens as correlates of infection, disease, immunity and targets for vaccination.
Coppola M; Ottenhoff TH
Semin Immunol; 2018 Oct; 39():88-101. PubMed ID: 30327124
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
8. Mycobacterium tuberculosis infection and vaccine development.
Tang J; Yam WC; Chen Z
Tuberculosis (Edinb); 2016 May; 98():30-41. PubMed ID: 27156616
[TBL] [Abstract][Full Text] [Related]
9. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
10. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
11. Antibiotic Treatment Shapes the Antigenic Environment During Chronic TB Infection, Offering Novel Targets for Therapeutic Vaccination.
Chuang YM; Dutta NK; Gordy JT; Campodónico VL; Pinn ML; Markham RB; Hung CF; Karakousis PC
Front Immunol; 2020; 11():680. PubMed ID: 32411131
[TBL] [Abstract][Full Text] [Related]
12. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection.
Lin MY; Ottenhoff TH
Biol Chem; 2008 May; 389(5):497-511. PubMed ID: 18953716
[TBL] [Abstract][Full Text] [Related]
13. TB drug development: immunology at the table.
Nathan C; Barry CE
Immunol Rev; 2015 Mar; 264(1):308-18. PubMed ID: 25703568
[TBL] [Abstract][Full Text] [Related]
14. Modulation of autophagy as a strategy for development of new vaccine candidates against tuberculosis.
Flores-Valdez MA; Segura-Cerda CA; Gaona-Bernal J
Mol Immunol; 2018 May; 97():16-19. PubMed ID: 29547747
[TBL] [Abstract][Full Text] [Related]
15. A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice.
Ahmed M; Smith DM; Hamouda T; Rangel-Moreno J; Fattom A; Khader SA
Vaccine; 2017 Sep; 35(37):4983-4989. PubMed ID: 28774560
[TBL] [Abstract][Full Text] [Related]
16. Genetics-directed drug discovery for combating Mycobacterium tuberculosis infection.
Quan Y; Xiong L; Chen J; Zhang HY
J Biomol Struct Dyn; 2017 Feb; 35(3):616-621. PubMed ID: 26900080
[TBL] [Abstract][Full Text] [Related]
17. Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention.
Lin MY; Ottenhoff TH
Endocr Metab Immune Disord Drug Targets; 2008 Mar; 8(1):15-29. PubMed ID: 18393920
[TBL] [Abstract][Full Text] [Related]
18. "The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report.
Boggiano C; Eichelberg K; Ramachandra L; Shea J; Ramakrishnan L; Behar S; Ernst JD; Porcelli SA; Maeurer M; Kornfeld H
Vaccine; 2017 Jun; 35(27):3433-3440. PubMed ID: 28476627
[TBL] [Abstract][Full Text] [Related]
19. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
20. Development of new antituberculous drugs based on bacterial virulence factors interfering with host cytokine networks.
Tomioka H; Tatano Y; Sano C; Shimizu T
J Infect Chemother; 2011 Jun; 17(3):302-17. PubMed ID: 21243398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
